Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  BOARD MEETINGS
Board Meetings      
Medicamen Biotech Ltd.
Source DateBoard Meeting DateDetails
07-Aug-2025 12-Aug-2025 Quarterly Results
22-May-2025 30-May-2025 Final Dividend & Audited Results
21-Feb-2025 26-Feb-2025 Preferential Issue of shares & Inter alia, to consider and approve a proposal for raising of funds by way of issuance of one or more instruments including equity shares/convertible securities either by way of Preferential Issue/Right Issue/QIP or any other mode.
04-Feb-2025 11-Feb-2025 Quarterly Results
07-Nov-2024 14-Nov-2024 Quarterly Results
07-Aug-2024 13-Aug-2024 Quarterly Results
21-May-2024 29-May-2024 Final Dividend & Audited Results
05-Feb-2024 12-Feb-2024 Quarterly Results
02-Nov-2023 10-Nov-2023 Quarterly Results
01-Aug-2023 08-Aug-2023 Quarterly Results
23-May-2023 29-May-2023 Final Dividend & Audited Results
31-Jan-2023 10-Feb-2023 Quarterly Results
04-Nov-2022 11-Nov-2022 Quarterly Results
03-Aug-2022 10-Aug-2022 Quarterly Results
27-Jul-2022 01-Aug-2022 Preferential Issue of shares
18-May-2022 25-May-2022 Final Dividend & Audited Results
02-Feb-2022 08-Feb-2022 Quarterly Results
25-Oct-2021 03-Nov-2021 Quarterly Results
06-Aug-2021 13-Aug-2021 Quarterly Results
18-Jun-2021 26-Jun-2021 Audited Results
Page 1 of 7
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.